MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
Be the first to know about new arrivals and promotions
Reducing Risk: 5 Steps for a Fearless Launch
